Immutep stock soars on promising trial results

Published 05/05/2025, 17:04
© Reuters.

Investing.com -- Shares of Immutep Ltd ADR (NASDAQ:IMMP) surged 37.4% following the announcement of favorable median Overall Survival (OS) data from its TACTI-003 Phase IIb trial. The trial evaluated eftilagimod alfa (efti) in combination with MSD’s KEYTRUDA® as a first-line therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) expressing low levels of PD-L1.

The company reported a median OS of 17.6 months in evaluable patients, a significant improvement over historical results from current standard-of-care approaches, which ranged from 7.9 to 11.3 months. This outcome positions efti, in combination with pembrolizumab, as a potential new treatment option for a patient population with limited current therapies.

The positive response to the news is attributed to the trial’s demonstration of a more than doubling in median OS compared to anti-PD-1 monotherapy, a standard treatment for this condition. The data, with a cut-off of March 31, 2025, also indicated that the combination therapy was well-tolerated, with no new safety concerns.

Marc Voigt, CEO of Immutep, emphasized the significant survival benefit for patients with ’cold tumors,’ which are less likely to respond to immunotherapies. He noted the potential of the combination therapy to provide more tolerable and effective treatments for patients with high unmet medical needs.

Looking ahead, Immutep has Fast Track designation for eftilagimod alfa in this indication and plans to consult with the U.S. Food and Drug Administration (FDA) to discuss approval pathways. The company will continue patient follow-up and data analysis, with further updates expected later in the year.

Investors reacted positively to the news, driving the stock up significantly during the trading session. The market’s response underscores the potential commercial and clinical impact of the therapy, as well as the company’s strategic position in addressing a challenging treatment landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.